Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THRX > SEC Filings for THRX > Form 8-K on 2-Sep-2014All Recent SEC Filings

Show all filings for THERAVANCE INC



Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

The information contained in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or incorporated by reference in any filing under the Securities Exchange Act of 1934 or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

GlaxoSmithKline plc (GSK) is scheduled to present data from Phase 3 studies of umeclidinium/vilanterol (UMEC/VI) and Phase 1 studies of the 'closed triple' combination fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) at the European Respiratory Society (ERS) Annual Congress, Munich, Germany to be held from September 6, 2014 through September 10, 2014. ANOROŽ ELLIPTAŽ is a once-daily combination treatment comprising two bronchodilators, UMEC, a long-acting muscarinic antagonist (LAMA), and VI, a long-acting beta2 agonist (LABA), in a single inhaler, the ELLIPTAŽ. FF/UMEC/VI is being investigated as a once-daily 'closed triple' combination treatment of an inhaled corticosteroid, a LAMA and a LABA in patients with COPD. A Phase 3 study of FF/UMEC/VI is currently ongoing. FF/UMEC/VI is not approved anywhere in the world. UMEC/VI has been developed and UMEC/FF/VI is being developed under the 2002 LABA collaboration between Glaxo Group Limited and Theravance, Inc. Titles and abstracts of poster presentations can be found in the ERS 2014 conference website

  Add THRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THRX - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.